Oral contraceptive use lowers endometrial cancer risk
by Bruce Sylvester: Oral contraceptive use appears to provide long-term protection against endometrial cancer, researchers reported on August 4, 2015 in The Lancet Oncology.
by Bruce Sylvester: Oral contraceptive use appears to provide long-term protection against endometrial cancer, researchers reported on August 4, 2015 in The Lancet Oncology.
Daily bathing of pediatric patients with disposable cloths containing 2 percent chlorhexidine gluconate (CHG) reduced central line-associated bloodstream infections (CLABSIs) by 59 percent and saved approximately $300,000 in… read more.
by Bruce Sylvester: Rociletinib, an investigative therapy for treatment resistant EGFR-mutation driven lung tumors, shows activity against the most common resistance mutation, and it significantly improves clinical outcomes.
by Gary Finnegan: People with terminal cancer often require palliative care in the late stages of their lives. This branch of medicine has long been lauded for the… read more.
by Gary Finnegan: Keytruda (pembrolizumab) has been recommended by the European Medicines Agency (EMA) as monotherapy for the treatment of adult patients with advanced melanoma that cannot be… read more.
by Gary Finnegan: Survival rates in young patients with high-risk neuroblastoma can be improved by Unituxin (dinutuximab), a new treatment approved by the European Medicines Agency (EMA).
by Bruce Sylvester: Investigators from the phase III PALOMA-3 trial report that treatment with the recently FDA-approved drug palbociclib more than doubled the time to cancer recurrence among… read more.
by Bruce Sylvester: Treatment of advanced melanoma with a combination of nivolumab (Opdivo™) and ipilimumab (Yervoy™) or with nivolumab alone increases progression-free survival over ipilimumab monotherapy, researchers reported… read more.
by Bruce Sylvester: Anastrozole is significantly more effective than tamoxifen in preventing cancer recurrence after lumpectomy and radiation therapy in postmenopausal women, age 60 or younger with DCIS… read more.
by Bruce Sylvester: Pembrolizumab (Keytruda®), an anti-PD-1 antibody immunotherapy has shown efficacy in one fourth of patients with recurrent or metastatic head and neck cancer, researchers reported on… read more.
by Bruce Sylvester: In a Phase III trial comparing standard docetaxel chemotherapy with immunotherapy nivolumab, researchers reported that subjects with squamous-non-small cell lung cancer treated with nivolumab lived… read more.
Psychologists are to improve online health information on lung cancer after research showed that family members are more likely to search online to encourage loved ones to seek… read more.
Advertisment